Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
How can aging be delayed? Graz-based heart scientist Mahmoud Abdellatif, MD PhD (Doctor of Medicine and Philosophy) has…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga…
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in…
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging funct…
Automatic Clay Brick Making Machine Market: IntroductionOver the century, the technique of manufacturing of clay brick h…
Over the century, the technique of manufacturing of clay brick has not experienced much change across the world. These a…
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…